Biobijou Reports Q1 2026 Consolidated Net Income of KRW 2.9B, Declares KRW 100 Dividend and Obtains Filler Product Approval

Consolidated Q1 2026 revenue KRW 8.0B (down from KRW 11.6B YoY), net income KRW 2.9B (up from KRW 1.7B YoY), EPS KRW 193.
Separate net income KRW 3.1B (up from KRW 2.5B YoY).
Final dividend for FY2025: KRW 100 per share cash (payout ratio 19.2%).
Obtained domestic KFDA approval for 'Colena Premium Filler Soft Molecule' in March 2026.
Debt-free, holds KRW 49B in cash & financial assets, debt ratio 6.9%.
High geographic concentration risk: China accounts for 78% of revenue.
R&D expenses KRW 132M (1.64% of sales).